Back

Targeting CX3CR1+ proinflammatory macrophages improves heart failure with preserved ejection fraction

31 August 2026 (08:35 - 08:45)
Organised by: Logo
Congress Presentation Part of: Immune-cardiac crosstalk and inflammation in cardiovascular disease Heart Failure ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Mr Julian Leberzammer

Wolfgang Goethe University, Frankfurt (Germany)

5 More presentations in this session

Presentation thumbnail
Unravelling the role and mechanisms of SK4 channels in atrial fibrillation: the immune-cardiac crosstalk
Mr J. Qin (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
A neonatal S100A8⁺ macrophage subset orchestrates inflammation resolution and cardiac regeneration after myocardial infarction
Miss H. Lu (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Sodium butyrate improves the cardiac immune microenvironment after myocardial ischemia-reperfusion injury by regulating macrophage polarization
Professor J. Gao (Tianjin, CN)
Abstract Slides Video
Presentation thumbnail
The mechanism of MsrB1 mediating the macrophage-endothelial reparative communication in myocardial ischemia reperfusion injury
Doctor M. Liu (Shanghai, CN)
Abstract Slides Video
Presentation thumbnail
A cardiomyocyte-intrinsic RXRγ–SOCS3 axis governs macrophage-driven inflammation in viral myocarditis
Doctor Z. Zhou (Wuhan, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Immune-cardiac crosstalk and inflammation in cardiovascular disease
Video

The Event

Event poster

ESC Congress 2026

31 August 2026 08:35 CET
You may be interested in
thumbnail
Congress Presentation
Fibrosis-related differences of endomyocardial immune infiltrates in heart failure with preserved ejection fraction
1 September 2025
thumbnail
Congress Presentation
KAND567, the first selective small molecule CX3CR1 antagonist in clinical development, mediates anti-inflammatory cardioprotective effects in rodent models of atherosclerosis and myocardial infarction
3 September 2019
thumbnail
Congress Presentation
Myeloperoxidase inhibitor AZD4831 target engagement and safety in a phase 2a study in patients with heart failure with preserved ejection fraction (SATELLITE)
1 July 2021
thumbnail
Congress Presentation
Linking brain innate immunity, energy metabolism, and HFpEF: hypothalamic complement C3/C3a/C3aR pathway drives cardiometabolic syndrome and HFpEF via central SOCS3 activation
18 May 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources